Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587776805> ?p ?o ?g. }
- W2587776805 endingPage "749" @default.
- W2587776805 startingPage "742" @default.
- W2587776805 abstract "Background AEZS-108 (zoptarelin doxorubicin) is a cytotoxic hybrid molecule consisting of doxorubicin covalently coupled with a luteinizing hormone-releasing hormone (LHRH) analogue, which selectively targets doxorubicin to tumor cells expressing LHRH receptors. We report the clinical efficacy of AEZS-108 in a phase II trial in men with metastatic castrate-resistant prostate cancer who had disease progression after taxane-based chemotherapy. Patients and Methods Patients received AEZS-108 210 mg/m2 intravenously every 3 weeks. The primary end point was clinical benefit defined as nonprogression at 12 weeks with no dose-limiting toxicities (DLTs) or other toxicities requiring termination of treatment. Secondary end points included response rate, pain response, progression-free survival (PFS), and overall survival (OS). Circulating tumor cells (CTCs) were captured and tested for LHRH receptors, as well as for internalization of AEZS-108 using autofluorescence. Results Twenty-five patients were enrolled; 20 patients had at least 1 measurable lesion at baseline. Patients received a median of 5 cycles (range, 1-9) and 44% of patients received at least 6 cycles with 2 patients who completed ≥ 8 cycles. Considering clinical benefits, 13 patients (52%) remained progression-free at 12 weeks with no DLT or other toxicities requiring termination of treatment. For clinical response according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria, 1 patient (4%) experienced a confirmed partial response (PR) within 12 weeks, 14 patients (56%) had stable disease (SD), and 8 patients (32%) had disease progression. For maximal prostate-specific antigen (PSA) response, 1 patient (4%) experienced a confirmed PR within 12 weeks, 21 patients (84%) had SD, and 3 patients (12%) had disease progression as denoted by their best PSA response. Pain improved in 13 (59%) patients. The median PFS was 3.8 months (95% confidence interval [CI], 2.1-4.4), and median OS was 6.0 months (95% CI, 4.2-10.1) with a median follow-up of 16.1 months (range, 3.2-36.1). Baseline CTC enumeration was an independent predictor of OS but not PFS. Conclusion AEZS-108 showed activity in patients who were pretreated, a subset typically very difficult to treat, and maintained an acceptable safety profile." @default.
- W2587776805 created "2017-02-24" @default.
- W2587776805 creator A5001948465 @default.
- W2587776805 creator A5020334875 @default.
- W2587776805 creator A5028279299 @default.
- W2587776805 creator A5031088617 @default.
- W2587776805 creator A5043871151 @default.
- W2587776805 creator A5047212274 @default.
- W2587776805 creator A5062167990 @default.
- W2587776805 creator A5066277505 @default.
- W2587776805 creator A5067387322 @default.
- W2587776805 creator A5068739269 @default.
- W2587776805 creator A5091696839 @default.
- W2587776805 date "2017-12-01" @default.
- W2587776805 modified "2023-10-17" @default.
- W2587776805 title "A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer" @default.
- W2587776805 cites W1527820373 @default.
- W2587776805 cites W1996092391 @default.
- W2587776805 cites W2041109673 @default.
- W2587776805 cites W2050006054 @default.
- W2587776805 cites W2080439368 @default.
- W2587776805 cites W2084688538 @default.
- W2587776805 cites W2087418545 @default.
- W2587776805 cites W2099367648 @default.
- W2587776805 cites W2110534364 @default.
- W2587776805 cites W2120292596 @default.
- W2587776805 cites W2123526148 @default.
- W2587776805 cites W2128302079 @default.
- W2587776805 cites W2130992263 @default.
- W2587776805 cites W2134788484 @default.
- W2587776805 cites W2148643283 @default.
- W2587776805 cites W2148998801 @default.
- W2587776805 cites W2150865892 @default.
- W2587776805 cites W2155843895 @default.
- W2587776805 cites W2158479847 @default.
- W2587776805 cites W2167331614 @default.
- W2587776805 cites W2336790777 @default.
- W2587776805 cites W4205145397 @default.
- W2587776805 doi "https://doi.org/10.1016/j.clgc.2017.06.002" @default.
- W2587776805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28668277" @default.
- W2587776805 hasPublicationYear "2017" @default.
- W2587776805 type Work @default.
- W2587776805 sameAs 2587776805 @default.
- W2587776805 citedByCount "21" @default.
- W2587776805 countsByYear W25877768052018 @default.
- W2587776805 countsByYear W25877768052019 @default.
- W2587776805 countsByYear W25877768052020 @default.
- W2587776805 countsByYear W25877768052021 @default.
- W2587776805 countsByYear W25877768052022 @default.
- W2587776805 countsByYear W25877768052023 @default.
- W2587776805 crossrefType "journal-article" @default.
- W2587776805 hasAuthorship W2587776805A5001948465 @default.
- W2587776805 hasAuthorship W2587776805A5020334875 @default.
- W2587776805 hasAuthorship W2587776805A5028279299 @default.
- W2587776805 hasAuthorship W2587776805A5031088617 @default.
- W2587776805 hasAuthorship W2587776805A5043871151 @default.
- W2587776805 hasAuthorship W2587776805A5047212274 @default.
- W2587776805 hasAuthorship W2587776805A5062167990 @default.
- W2587776805 hasAuthorship W2587776805A5066277505 @default.
- W2587776805 hasAuthorship W2587776805A5067387322 @default.
- W2587776805 hasAuthorship W2587776805A5068739269 @default.
- W2587776805 hasAuthorship W2587776805A5091696839 @default.
- W2587776805 hasConcept C121608353 @default.
- W2587776805 hasConcept C126322002 @default.
- W2587776805 hasConcept C126894567 @default.
- W2587776805 hasConcept C143998085 @default.
- W2587776805 hasConcept C203092338 @default.
- W2587776805 hasConcept C2776235491 @default.
- W2587776805 hasConcept C2776694085 @default.
- W2587776805 hasConcept C2777511904 @default.
- W2587776805 hasConcept C2780192828 @default.
- W2587776805 hasConcept C2781303535 @default.
- W2587776805 hasConcept C31760486 @default.
- W2587776805 hasConcept C530470458 @default.
- W2587776805 hasConcept C535046627 @default.
- W2587776805 hasConcept C71924100 @default.
- W2587776805 hasConceptScore W2587776805C121608353 @default.
- W2587776805 hasConceptScore W2587776805C126322002 @default.
- W2587776805 hasConceptScore W2587776805C126894567 @default.
- W2587776805 hasConceptScore W2587776805C143998085 @default.
- W2587776805 hasConceptScore W2587776805C203092338 @default.
- W2587776805 hasConceptScore W2587776805C2776235491 @default.
- W2587776805 hasConceptScore W2587776805C2776694085 @default.
- W2587776805 hasConceptScore W2587776805C2777511904 @default.
- W2587776805 hasConceptScore W2587776805C2780192828 @default.
- W2587776805 hasConceptScore W2587776805C2781303535 @default.
- W2587776805 hasConceptScore W2587776805C31760486 @default.
- W2587776805 hasConceptScore W2587776805C530470458 @default.
- W2587776805 hasConceptScore W2587776805C535046627 @default.
- W2587776805 hasConceptScore W2587776805C71924100 @default.
- W2587776805 hasFunder F4320332161 @default.
- W2587776805 hasFunder F4320337351 @default.
- W2587776805 hasIssue "6" @default.
- W2587776805 hasLocation W25877768051 @default.
- W2587776805 hasLocation W25877768052 @default.
- W2587776805 hasOpenAccess W2587776805 @default.
- W2587776805 hasPrimaryLocation W25877768051 @default.
- W2587776805 hasRelatedWork W1980245127 @default.